Drug Approval | April 10, 2023
Virpax reports on progress of Envelta
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Bourgoin early development hub broadens offerings for oral solid dose formulations
Venkat Nageswar Chalasani has been appointed as an Independent Director of Apitoria Pharma with effect from April 4, 2023
Extends patent protection for Microbion's proprietary inhaled pravibismane for the treatment of pulmonary infections to 2039
The disease is caused by a mutation in the gene encoding HMG CoA reductase, inhibiting the enzyme’s activity.
Vikas Vij has been appointed as Chief Executive Officer (CEO) of the company
Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers
Loperamide Hydrochloride Capsules USP, 2 mg had annual sales of US $34.7 million in the United States
Pre-filled pens containing a combination of insulin glargine 100 Units/mL and lixisenatide for once-daily dosing
hubergroup’s two newly added medical vans are dedicated to dental and eye care
Subscribe To Our Newsletter & Stay Updated
